NCT03845582 - Phase 2/3 Study of ALK-001 in Geographic Atrophy | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

May 7, 2019

Primary Completion Date

July 25, 2023

Study Completion Date

June 30, 2024

Conditions

Geographic AtrophyAge Related Macular DegenerationAMDAtrophy, Geographic

Interventions

DRUG

ALK-001 oral capsule

Daily administration for 24 months

DRUG

Placebo oral capsule

Daily administration for 24 months

Trial Locations (24)

11021

Alkeus Site, Great Neck

11788

Alkeus Site, Hauppauge

20815

Alkeus Site, Chevy Chase

22031

Alkeus Site, Fairfax

32601

Alkeus Site, Gainesville

33609

Alkeus Site, Tampa

33761

Alkeus Site, Clearwater

33880

Alkeus Site, Winter Haven

33912

Alkeus Site, Fort Myers

40509

Alkeus Site, Lexington

44122

Alkeus Site, Cleveland

49546

Alkeus Site, Grand Rapids

55435

Alkeus Site, Edina

61704

Alkeus Site, Bloomington

77025

Alkeus Site, Houston

78240

Alkeus Site-1, San Antonio

Alkeus Site-2, San Antonio

80228

Alkeus Site, Lakewood

85053

Alkeus Site, Phoenix

90211

Alkeus Site, Beverly Hills

97520

Alkeus Site, Ashland

98383

Alkeus Site, Silverdale

01605

Alkeus Site, Worcester

08225

Alkeus Site, Northfield